FDA, Spravato and major depressive disorder

FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
FDA approves nasal spray for treatment-resistant depression
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.
FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
JNJ's SNDA For Spravato Monotherapy Gets FDA Approval For Treatment-Resistant Depression
Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with treatment-resistant depression, a psychiatric disorder.
Medscape10d
Brief Treatment Strategies for Major Depressive Disorder: Advice for the Primary Care Clinician
Major depressive disorder ... of sessions and the type of treatment that can be provided, it has become important for clinicians to identify how they can best fulfill this mandate.
Using machine learning to predict how people diagnosed with major depressive disorder respond to treatment
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
Healthline17d
Your Guide to Understanding Depression in Elderly and Older Adults
Depression in older adults, also called geriatric depression, is a mental and emotional disorder affecting older adults. Feelings of sadness and occasional “blue” moods are normal. However ...
Medscape4d
Second-generation Antipsychotics in the Treatment of Major Depressive Disorder
Major depressive disorder ... remit following adequate antidepressant treatment, while most MDD patients suffer from significant core depressive or residual symptoms during their clinical ...
Hosted on MSN1d
Magnetic stimulation for brain offering help for major depression
A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.